Giovannoni Isabella, Callea Francesco, Boldrini Renata, Inserra Alessandro, Cozza Raffaele, Francalanci Paola
1 Department of Pathology, Children's Hospital Bambino Gesù, IRCCS Rome, Italy.
Pediatr Dev Pathol. 2014 Mar-Apr;17(2):126-9. doi: 10.2350/13-10-1397-CR.1. Epub 2014 Feb 20.
Patients with neurofibromatosis type I (NF1) feature a high risk of developing benign and malignant tumors, mainly those with a neuroectodermal origin, the risk being about 4 times higher than in the general population. Pheochromocytoma (PHEO) is a sporadic tumor (1∶100,000) arising from the adrenal medulla. Pheochromocytoma is a rare condition when occurring in conjunction with NF1 and occurs in about 1% of patients, rarely in those of pediatric age. In this study we present a 16-year-old patient with NF1 and malignant PHEO. Loss of heterozygosity analysis in PHEOs shows a reduction to homozygosity, observed for both 17p and 17q markers. This case confirms the importance of surveillance for malignant neoplasias in NF1 patients during childhood and adolescence. On the other hand, since 30% of PHEOs had germline mutations and, more rarely, somatic mutations, patients with PHEO should be investigated for associated genetic syndromes.
I型神经纤维瘤病(NF1)患者发生良性和恶性肿瘤的风险很高,主要是那些起源于神经外胚层的肿瘤,其风险比一般人群高约4倍。嗜铬细胞瘤(PHEO)是一种起源于肾上腺髓质的散发性肿瘤(1∶100,000)。嗜铬细胞瘤与NF1同时发生时较为罕见,约1%的NF1患者会出现,儿童患者中则更为少见。在本研究中,我们报告了一名患有NF1和恶性PHEO的16岁患者。对嗜铬细胞瘤进行杂合性缺失分析显示,17p和17q标记均出现纯合性降低。该病例证实了在儿童和青少年时期对NF1患者进行恶性肿瘤监测的重要性。另一方面,由于30%的嗜铬细胞瘤存在种系突变,体细胞突变则更为罕见,因此应对嗜铬细胞瘤患者进行相关遗传综合征的调查。